Ovarian Cancer Market Report 2024 (Global Edition)

Global Ovarian Cancer Market Report 2024 Market Size Split by Type (Epithelial Tumors, Germ Cell Tumors, Stromal Tumors, Primary Peritoneal Cancer), by End-User (Hospitals, Diagnostic Centers, Drug St...

Ovarian Cancer Market Report Description

We have various report editions of Ovarian Cancer Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Ovarian Cancer Market

The competitive landscape of the ovarian cancer market is characterized by intense rivalry among industry players striving to innovate diagnostics, treatments, and supportive care solutions. Key focus areas include research and development, market expansion strategies, and differentiation through product efficacy, safety, and affordability.

Top Companies Market Share in Ovarian Cancer Industry: (In no particular order of Rank)

• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co. Inc.
• Allergan
• AstraZeneca
• Johnson & Johnson Private Limited
• Cipla Inc.
• Abbott
• AbbVie Inc.
• Merck KGaA
• LEO Pharma A/S
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals LLC.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Ovarian Cancer Market 

Which Region Dominates the Market Ovarian Cancer in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue due to factors such as high healthcare expenditure, advanced healthcare infrastructure, and early adoption of novel therapies. Additionally, favourable reimbursement policies, strong research and development activities, and a large patient pool contribute to market dominance. Moreover, increasing awareness campaigns, emphasis on preventive care, and rising prevalence rates drive demand for ovarian cancer diagnostics and treatments in the region.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is the fastest-growing region due to expanding healthcare access, rising disposable incomes, and improving awareness about ovarian cancer. Moreover, the region's large population base, particularly in countries like China and India, drives demand. Additionally, technological advancements, growing investments in healthcare infrastructure, and supportive government initiatives further fuel market growth. Furthermore, collaborations between global pharmaceutical companies and local healthcare providers enhance treatment availability and affordability, contributing to market expansion in Asia-Pacific.

The current report Scope analyzes Ovarian Cancer Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Ovarian Cancer Market

According to Cognitive Market Research, the global ovarian cancer market size was estimated at USD 1751.2 Million out of which North America held the major market of around 40% of the global revenue with a market size of USD 700.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.5% from 2024 to 2031. Sales of ovarian cancer treatments are set to rise in North America due to factors such as robust healthcare infrastructure, high prevalence rates, and increasing awareness campaigns. Moreover, advancements in precision medicine and targeted therapies drive demand for innovative treatment options. Additionally, supportive regulatory frameworks expedite market access for new therapies, fostering market growth. In this region, hospitals dominate the market share, poised to grow further owing to their comprehensive care offerings and specialized oncology departments. Increased adoption of surgery as a primary treatment method further bolsters market expansion in North America.

Country Analysis

• According to Cognitive Market Research, The United States ovarian cancer market had a market share of USD 552.68 million in 2024 and is projected to grow at a CAGR of 22.3% during the forecast period. Sales of ovarian cancer treatments in the U.S. are poised to increase due to advanced healthcare infrastructure, high prevalence rates, robust research, and development, and a supportive regulatory environment fostering innovation.
• Canada ovarian cancer market had a market share of USD 84.06 million in 2024 and is projected to grow at a CAGR of 23.3% during the forecast period. In Canada, sales of ovarian cancer treatments are expected to rise owing to increasing healthcare expenditure, expanding access to healthcare services, and growing awareness campaigns promoting early detection and treatment.
• Mexico ovarian cancer market had a market share of USD 63.74 million in 2024 and is projected to grow at a CAGR of 23.0% during the forecast period.

Europe Ovarian Cancer Market

According to Cognitive Market Research, with a market value of USD 1751.2 million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 22.8% from 2024 to 2031. Europe accounted for a share of around 30% of the global market size of USD 525.36 million. In Europe, sales of ovarian cancer treatments are expected to increase due to improving healthcare access, rising incidence rates, and government initiatives promoting early detection. Furthermore, collaborations between academia and industry drive innovation in diagnostics and therapeutics, enhancing treatment efficacy. Additionally, the presence of leading pharmaceutical companies fosters research and development activities, leading to the introduction of novel treatment modalities. Notably, targeted therapy emerges as the fastest-growing segment in Europe, driven by advancements in molecular profiling and personalized medicine, further boosting market growth.

• The United Kingdom ovarian cancer market had a market share of USD 88.26 million in 2024 and is projected to grow at a CAGR of 23.6% during the forecast period. The UK's ovarian cancer treatment sales are set to increase due to improved screening programs, advancements in precision medicine, and collaborations between academia and industry driving innovation in diagnostics and therapeutics.
• France ovarian cancer market had a market share of USD 48.33 million in 2024 and is projected to grow at a CAGR of 22.0% during the forecast period.
• Germany ovarian cancer market had a market share of USD 104.02 million in 2024 and is projected to grow at a CAGR of 23.0% during the forecast period. Sales of ovarian cancer treatments in Germany are expected to increase due to a well-established healthcare system, emphasis on preventive care, and adoption of innovative treatment modalities such as targeted therapy and immunotherapy.
• Italy ovarian cancer market had a market share of USD 45.18 million in 2024 and is projected to grow at a CAGR of 22.2% during the forecast period.
• Russia ovarian cancer market had a market share of USD 81.43 million in 2024 and is projected to grow at a CAGR of 21.8% during the forecast period.
• Spain ovarian cancer market had a market share of USD 43.08 million in 2024 and is projected to grow at a CAGR of 21.9% during the forecast period.
• Luxembourg ovarian cancer market had a market share of USD 16.29 million in 2024 and is projected to grow at a CAGR of 22.9% during the forecast period.
• Portugal ovarian cancer market had a market share of USD 11.03 million in 2024 and is projected to grow at a CAGR of 22.6% during the forecast period.
• Greece ovarian cancer market had a market share of USD 6.30 million in 2024 and is projected to grow at a CAGR of 23.1% during the forecast period.
• Rest of Europe ovarian cancer market had a market share of USD 81.43 million in 2024 and is projected to grow at a CAGR of 21.5% during the forecast period.

Asia Pacific Ovarian Cancer Market

According to Cognitive Market Research, the global ovarian cancer market size was estimated at USD 1751.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 402.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 26.3% from 2024 to 2031. The Asia Pacific region witnesses a surge in ovarian cancer treatment sales attributed to increasing healthcare investments, rising disposable incomes, and expanding awareness programs. Additionally, the adoption of telemedicine and digital health solutions enhances access to healthcare services, particularly in remote areas. Moreover, the fast-growing economies of countries like China and India contribute to market expansion. Magnetic resonance imaging (MRI) scans emerge as the fastest-growing segment in Asia Pacific, driven by technological advancements and growing demand for accurate diagnostic tools in the region.

• According to Cognitive Market Research, The China ovarian cancer market had a market share of USD 181.25 million in 2024 and is projected to grow at a CAGR of 25.8% during the forecast period. In China, sales of ovarian cancer treatments are on the rise due to increasing healthcare investments, rising disposable incomes, and expanding access to advanced medical technologies and treatments in urban centres.
• Japan's ovarian cancer market had a market share of USD 55.58 million in 2024 and is projected to grow at a CAGR of 24.8% during the forecast period.
• India's ovarian cancer market had a market share of USD 48.33 million in 2024 and is projected to grow at a CAGR of 28.1% during the forecast period. India witnesses a surge in ovarian cancer treatment sales due to rising awareness, improving healthcare infrastructure, and growing investments in oncology research and development, leading to the introduction of advanced treatment options.
• South Korea's ovarian cancer market had a market share of USD 40.28 million in 2024 and is projected to grow at a CAGR of 25.4% during the forecast period.
• Australia's ovarian cancer market had a market share of USD 20.94 million in 2024 and is projected to grow at a CAGR of 26.0% during the forecast period.
• The ovarian cancer market in South East Asia had a market share of USD 27.79 million in 2024 and is projected to grow at a CAGR of 27.3% during the forecast period.
• The Rest of Asia Pacific ovarian cancer market had a market share of USD 28.60 million in 2024 and is projected to grow at a CAGR of 26.1% during the forecast period.

South America Ovarian Cancer Market

According to Cognitive Market Research, the global ovarian cancer market size was estimated at USD 1751.2 Million out of which Latin America market of around 5% of the global revenue with a market size of USD 87.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 23.7% from 2024 to 2031. Sales of ovarian cancer treatments in Latin America are on the rise due to improving healthcare infrastructure, growing investments in oncology, and rising awareness among the population. Furthermore, collaborations between public and private sectors bolster research and development efforts, leading to the introduction of novel therapies. Additionally, favourable regulatory policies and increasing access to healthcare services drive market growth. Chemotherapy stands out as the fastest-growing segment in Latin America, driven by its widespread adoption as a primary treatment modality across the region.

• According to Cognitive Market Research, Brazil's ovarian cancer market had a market share of USD 37.48 million in 2024 and is projected to grow at a CAGR of 24.3% during the forecast period. Sales of ovarian cancer treatments in Brazil are expected to increase owing to expanding healthcare access, rising prevalence rates, and government initiatives aimed at improving cancer care services and infrastructure across the country.
• Argentina's ovarian cancer market had a market share of USD 14.71 million in 2024 and is projected to grow at a CAGR of 24.6% during the forecast period. In Argentina, sales of ovarian cancer treatments are set to rise due to increasing healthcare investments, growing awareness about women's health, and adoption of advanced medical technologies and treatment modalities.
• Colombia's ovarian cancer market had a market share of USD 7.79 million in 2024 and is projected to grow at a CAGR of 23.5% during the forecast period.
• Peru's ovarian cancer market had a market share of USD 7.18 million in 2024 and is projected to grow at a CAGR of 23.9% during the forecast period.
• Chile's ovarian cancer market had a market share of USD 6.30 million in 2024 and is projected to grow at a CAGR of 24.0% during the forecast period.
• The ovarian cancer market in the rest of Latin America had a market share of USD 14.10 million in 2024 and is projected to grow at a CAGR of 22.8% during the forecast period.

Middle East and Africa Ovarian Cancer Market

According to Cognitive Market Research, the global ovarian cancer market size was estimated at USD 1751.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 35.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 24.0% from 2024 to 2031. In the Middle East and Africa (MEA), sales of ovarian cancer treatments are increasing due to improving healthcare access, rising awareness about women's health, and government initiatives to tackle cancer. Additionally, partnerships with international organizations facilitate knowledge exchange and capacity building in oncology. Moreover, the adoption of telemedicine and mobile health solutions enhances patient care in remote areas. Notably, surgery holds the highest market share in MEA, driven by its essential role in both diagnosis and treatment of ovarian cancer, coupled with increasing investments in surgical oncology infrastructure.

• According to Cognitive Market Research, The GCC Countries ovarian cancer market had a market share of USD 14.99 million in 2024 and is projected to grow at a CAGR of 24.8% during the forecast period. Sales of ovarian cancer treatments in GCC countries are expected to increase due to government investments in healthcare infrastructure, rising prevalence rates, and initiatives to enhance cancer care services and access to advanced treatments.
• Egypt's ovarian cancer market had a market share of USD 3.68 million in 2024 and is projected to grow at a CAGR of 24.3% during the forecast period.
• South Africa's ovarian cancer market had a market share of USD 5.53 million in 2024 and is projected to grow at a CAGR of 25.0% during the forecast period. In South Africa, sales of ovarian cancer treatments are poised to increase owing to improving healthcare access, rising awareness campaigns, and government efforts to address healthcare disparities and enhance oncology services across the country.
• Turkey's ovarian cancer market had a market share of USD 3.01 million in 2024 and is projected to grow at a CAGR of 23.5% during the forecast period.
• Nigeria's ovarian cancer market had a market share of USD 3.68 million in 2024 and is projected to grow at a CAGR of 23.1% during the forecast period.
• The Rest of MEA ovarian cancer market had a market share of USD 4.13 million in 2024 and is projected to grow at a CAGR of 23.0% during the forecast period.

Ovarian Cancer Market Analysis

Ovarian Cancer Type Segment Analysis

• Epithelial Tumors
• Germ Cell Tumors
• Stromal Tumors
• Primary Peritoneal Cancer

According to Cognitive Market Research, epithelial tumours held the major market share over the forecast period due to their high prevalence among ovarian cancer subtypes, driving demand for diagnostic tests and treatment options. Additionally, advancements in targeted therapies and immunotherapies tailored specifically for epithelial tumours boost market growth. Moreover, rising awareness campaigns, early detection initiatives, and improved screening methods contribute to increased diagnosis rates, further fuelling sales within this segment.

Germ cell tumours are the fastest-growing category over the forecast period owing to the increasing incidence of this subtype, particularly among younger demographics. Additionally, advancements in genetic testing and personalized medicine enable more accurate diagnosis and tailored treatment approaches for germ cell tumours, driving demand. Furthermore, research into novel therapeutic modalities, such as targeted therapies and immunotherapies, enhances treatment efficacy and expands the market potential for this rapidly growing category.

•    For instance, In September 2022, AstraZeneca and Merck announced that Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.

(Source:https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-china-for-ovarian-cancer.html)

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Ovarian Cancer Industry. Request a Free Sample PDF!

Ovarian Cancer End-user Segment Analysis

• Hospitals

• Diagnostic Centers

• Drug Stores

• Online Pharmacies

• Other End Users

According to Cognitive Market Research, hospitals hold a prominent market share due to their central role in providing comprehensive care for ovarian cancer patients. Hospitals offer a wide range of diagnostic services, treatment modalities, and supportive care under one roof, making them a preferred choice for many patients. Additionally, hospitals often have specialized oncology departments equipped with state-of-the-art facilities and multidisciplinary teams, attracting patients seeking specialized care. Furthermore, partnerships between hospitals and research institutions facilitate access to cutting-edge treatments and clinical trials, further boosting sales.

Online pharmacies are the fastest-growing category over the forecast period due to the convenience, accessibility, and cost-effectiveness they offer. Patients can conveniently order medications from the comfort of their homes, eliminating the need for physical visits to traditional pharmacies. Moreover, online pharmacies often provide a wider range of options, including generic alternatives, at competitive prices, attracting cost-conscious consumers. Additionally, the COVID-19 pandemic has accelerated the shift towards online healthcare services, further driving sales in this segment

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Ovarian Cancer Diagnosis Segment Analysis

According to Cognitive Market Research, ultrasound hold a prominent market share due to their widespread availability, affordability, and non-invasive nature, making them a preferred choice for initial screening and monitoring of ovarian cancer. Additionally, technological advancements have led to the development of more advanced ultrasound techniques, such as trans-vaginal and 3D/4D imaging, enhancing diagnostic accuracy and patient outcomes. Moreover, the portability of ultrasound machines allows for point-of-care testing in various healthcare settings, further driving market growth.

Magnetic resonance imaging (MRI) scans is the fastest-growing category over the forecast period due to their superior imaging capabilities, providing detailed anatomical information essential for accurate ovarian cancer diagnosis and staging. Additionally, advancements in MRI technology, such as functional MRI and diffusion-weighted imaging, offer improved sensitivity and specificity in detecting ovarian tumours. Furthermore, the growing adoption of MRI-guided interventions, such as biopsy and targeted therapy delivery, enhances the clinical utility of MRI scans, driving market growth in this segment.

• Computed Tomography (C.T.) Scans
• Ultrasound
• Barium Enema X-Ray
• Magnetic Resonance Imaging (MRI) Scans
• Chest X-Ray
• Positron Emission Tomography (PET) Scan
• Other Diagnostic Tests

Ovarian Cancer Therapeutic Treatment Segment Analysis

• Chemotherapy

• Radiation Therapy

• Targeted Therapy

• Hormone Therapy

• Surgery

• Other Therapeutic Treatments

According to Cognitive Market Research, Targeted therapy is the dominating category over the forecast period due to the increasing recognition of its efficacy and specificity in treating ovarian cancer. Targeted therapies, such as PARP inhibitors and angiogenesis inhibitors, selectively target cancer cells while sparing healthy tissues, reducing adverse effects and improving patient outcomes. Moreover, ongoing research into biomarkers and molecular pathways associated with ovarian cancer enables the development of more tailored and effective targeted therapies, driving market growth in this rapidly evolving segment.. 
•    For instance, Bevacizumab, an angiogenesis inhibitor administered to patients with ovarian cancer as targeted therapy, is proven to shrink and slow the growth of advanced epithelial ovarian cancers.

(Source
https://www.cancer.org/cancer/types/ovarian-cancer/treating/targeted-therapy.html

•    For instance, on 6 June 2023, Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced intermittent phase 2 dose (RP2D) azenosertib monotherapy for developing clinically differentiated small molecule targeting the fundamental biological pathways of ovarian cancer. This transitional monotherapy dosing doubles efficiency over constant dosing to achieve efficacy signals with safety and improved tolerability.

(Source:https://ir.zentalis.com/news-releases/news-release-details/zentalis-announces-intermittent-azenosertib-monotherapy-dosing)
Surgery hold a fastest-groing market share due to its crucial role in both the diagnostic and treatment phases. Surgical procedures such as oophorectomy and debulking surgery are fundamental in removing tumours and staging the disease. Moreover, advancements in surgical techniques, including minimally invasive procedures like laparoscopy, reduce recovery times and complications, driving patient preference and increasing sales. Additionally, the integration of robotics and navigation systems enhances surgical precision and outcomes, further contributing to market growth.

• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Hormone Therapy
• Surgery
• Other Therapeutic Treatments

Ovarian Cancer Route of Administration Segment Analysis

• Oral

• Parenteral

• Others

According to Cognitive Market Research, oral hold a prominent market share due to factors such as patient convenience, ease of administration, and improved drug formulations. Oral medications offer patients flexibility in managing their treatment schedules and can be taken at home, reducing the need for frequent hospital visits. Additionally, the development of novel oral formulations with enhanced bioavailability and reduced side effects enhances patient adherence and satisfaction, driving sales in this segment.

Parenteral is the fastest-growing category over the forecast period attributed to several factors, including the immediate onset of action, higher bioavailability, and suitability for patients unable to tolerate oral medications. Parenteral formulations, such as intravenous and intramuscular injections, offer rapid drug delivery and precise dosing, crucial for managing ovarian cancer symptoms and complications effectively. Moreover, advancements in drug delivery technologies, such as nanoparticle formulations and sustained-release systems, further enhance the efficacy and safety of parenteral treatments, driving market growth in this segment.
•    For instance, on 6 May 2021, the FDA approved the commencement of endoxifen research for ovarian cancer treatment where a patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of FDA-approved tamoxifen.

(Source:https://www.targetedonc.com/view/fda-okays-initiation-of-endoxifen-study-in-ovarian-cancer)

• Oral
• Parenteral
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion